Portal vein thrombosis, hepatic decompensation, and survival in patients with porto-sinusoidal vascular disease and portal hypertension
Journal of Gastroenterology · 2023
DOI: 10.1007/s00535-023-01957-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology, 2023. Verfasst von Xiaocen Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Iowa, 200 Hawkins Drive, Iowa City, IA, USA. Hauptthemen laut MEDLINE: Idiopathic Noncirrhotic Portal Hypertension, End Stage Liver Disease, Budd-Chiari Syndrome, Hypertension, Portal. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Porto-sinusoidal vascular disease (PSVD) is a novel nomenclature to describe non-cirrhotic portal hypertension and characteristic histology without portal vein thrombosis (PVT). It is a more inclusive definition than the previously well-recognized entity idiopathic non-cirrhotic portal hypertension. There is a paucity of data on PSVD patients. METHODS: A total of 33 patients diagnosed with PSVD and portal hypertension (PH) between 2005 and 2021 were included. Data were retrieved from electronic medical record system and analyzed. RESULTS: Of the 33 patients, 6 (18%) occurred in post-transplant allograft liver. After a median follow-up of 96 months (interquartile range, IQR [52, 139]), 14 deaths occurred (42%), 4 directly related to decompensated liver disease. The Kaplan-Meier survival estimates at 1, 5, and 10 years were 94%, 87% and 58%. PVT occurred in 10 patients (30%). The Nelson-Aalen cumulative risk estimate for PVT at 1, 5 and 10 years were 16%, 25% and 48%. The median model for end-stage liver disease and Child-Pugh score at initial presentation were 8 (IQR [7-12]) and 5 [5-6], and increased to 13 [8, 18] and 7 [5, 8], respectively, at the end of follow-up. Of the 11 patients who presented with splenomegaly and no specific sign of PH, 7 (64%) developed varices and 3 (27%) ascites at a median follow-up of 100 months. CONCLUSIONS: PSVD with PH is not a benign entity. Mortality, PVT and hepatic decompensation are common. Patients with PSVD must be closely monitored, including those who only have non-specific clinical signs (e.g., splenomegaly) of PH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Iowa, 200 Hawkins Drive, Iowa City, IA, USA.
- Department of Internal Medicine, University of Iowa, 200 Hawkins Drive, Iowa City, IA, USA.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Iowa, 200 Hawkins Drive, Iowa City, IA, USA. arvindrm13@gmail.com.
- Liver Center, Orlando Health Digestive Health Institute, 89 W. Copeland Dr., Orlando, FL, USA. arvindrm13@gmail.com.
ORCID-Profile: Arvind R Murali
Zitieren
APA
Zhang, X., Durham, K. M., Garza, A. A., & Murali, A. R. (2023). Portal vein thrombosis, hepatic decompensation, and survival in patients with porto-sinusoidal vascular disease and portal hypertension. Journal of Gastroenterology. https://doi.org/10.1007/s00535-023-01957-0
Vancouver
Zhang X, Durham KM, Garza AA, Murali AR. Portal vein thrombosis, hepatic decompensation, and survival in patients with porto-sinusoidal vascular disease and portal hypertension. Journal of Gastroenterology. 2023. doi:10.1007/s00535-023-01957-0
BibTeX
@article{Zhang2023,
author = {Zhang, Xiaocen and Durham, Katelin Marie and Garza, Alexander Austin and Murali, Arvind R},
title = {Portal vein thrombosis, hepatic decompensation, and survival in patients with porto-sinusoidal vascular disease and portal hypertension},
journal = {Journal of Gastroenterology},
year = {2023},
doi = {10.1007/s00535-023-01957-0}
}
EUVIMED